Skip to main content
Kane Biotech
Biofilms
Overview
Understanding Biofilms
coactiv+™
DispersinB
®
Glossary Of Terms
Commercialization Vehicles
Overview
Kane Wound Care & Surgical
Kane Dermatology
About
Overview
Our Team
Careers
Contact
Publications
Blog
Publications / Posters
News / Events
Investors
Overview
News / Events
Company Information
Financial Results
Stock Data
SEDAR
Corporate Governance
Press Releases
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Investors
Overview
News / Events
Press Releases
IR Calendar
Email Alerts
Company Info
Profile
Overview of Kane Wound Care
DermaKB OTC Shampoo Trials
Presentations
Management Team
Contacts
Financial Results
Stock Data
TSX-V:KNE
OTCQB:KNBIF
SEDAR
Governance
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
News / Events
Press Releases
IR Calendar
Email Alerts
All News
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Kane Biotech Issued US Patent for DispersinB(R) Wound Care Technology
Nov 16, 2010
DispersinB(R) Topical Wound Spray Passes Critical Sensitization Test
Nov 8, 2010
Kane Biotech Appoints Board Advisor and Announces Private Placement Offering
Nov 2, 2010
Kane Biotech Selected as One of Canada's Top 10(TM) Life Sciences Companies
Oct 14, 2010
DispersinB(R) Wound Spray Passes First Set of Biocompatibility Tests
Oct 4, 2010
DispersinB(R) Wound Spray Passes Quality Control and Sterility Tests
Sep 30, 2010
Kane Biotech Announces Grant of Options
Sep 29, 2010
Kane Biotech Develops DispersinB(R) Monoclonal Antibodies
Sep 21, 2010
Kane Biotech Appoints Mr. Philip Renaud to Board of Directors
Sep 15, 2010
Kane Biotech Appoints Dr. Jeffrey B. Kaplan to Scientific Advisory Board
Jul 20, 2010
1...
29
30
31
32
33
34
35
36
37
38